Haiying Sun

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 335 citations · Full text

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Qian Cai, Haiying Sun, Yuefeng Peng et al. · Journal of Medicinal Chemistry · 2011 · 265 citations · Full text

Design, Synthesis, and Characterization of a Potent, Nonpeptide, Cell-Permeable, Bivalent Smac Mimetic That Concurrently Targets Both the BIR2 and BIR3 Domains in XIAP

Haiying Sun, Zaneta Nikolovska‐Coleska, Jianfeng Lü et al. · Journal of the American Chemical Society · 2007 · 200 citations · Full text

SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

Jianfeng Lü, Longchuan Bai, Haiying Sun et al. · Cancer Research · 2008 · 200 citations · Full text

Tumor Regression, Apoptosis Protein, Apoptosis +18

Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase Akt

Alan P. Kozikowski, Haiying Sun, John Brognard et al. · Journal of the American Chemical Society · 2003 · 196 citations

Chemoprevention Strategy, Cell Death, Medicinal Chemistry +17